Lupin Looks To Be First Out Of The Blocks On US Ingrezza, With Zydus Second
US Ingrezza Legal Battles Wrapped Up, With Earlier Teva, Sandoz Deals
ANDA sponsors targeting Neurocrine Biosciences’ Ingrezza (valbenazine) blockbuster are in position to launch – albeit with a 14-year wait that validates the strength of the originator’s IP.
